【摘要】 目的观察尿激酶静脉溶栓治疗急性脑梗死不同时间窗的有效性和安全性。方法采用开放研究方法对发病6 h内的A组30例,发病6~12 h的B组40例急性脑梗死患者,给予快速静脉滴注尿激酶100~150万U治疗。另设30例未用尿激酶治疗的急性脑梗死患者(C组)作为对照组。两组其余治疗方法相同。分别对治疗前后各组患者神经功能缺损积分变化进行评定,并用TCD评价血管再通情况。结果A组、B组与C组比较,神经功能缺损评分及血管再通率等指标有显著性差异(P<0.01,P<0.05)。A、B两组比较,神经功能缺损评分及脑内出血率有显著性差异(P<0.05),但血管再通率两组间无差别(P>0.05)。结论静脉滴注尿激酶溶栓,6 h内疗效显著,并发症少,6~12 h溶栓也有明显效果。更多还原

【Abstract】 Objective To explore the therapeutic effects and safety of urokinase in treating acute cerebral infarcion.Methods Intravenous injection of(1～1.5)×106 units of urokinease was used to treat 30 cases of acute infarction in Group A within 6 hours of first attack and 40 cases in Group B.Another 30 cases in Group C were not treated with urakinase.The changes in the integral of the nerve function defect were evaluated before and after the treatments in all groups.TCD evaluation was conducted to analyze the re-opening of blood vessels.Results Group A and Group B got better curative effects than Group C in terms of nerve function defect evaluation and the rate of reopeing of blood vessels(P<0.01,P<0.05).Group A and Group B showed significant difference in terms of nerve function defect evaluation and the rate of intracerebral hemorrhage(P<0.05),but not in terms of the re-opening of blood vessels(P>0.05).Conclusion Urokinase can be used effectively to treat acute cerebral infarction with less complications within 6 hours of attack and can also produce good effects 6～12 hours after the attack.更多还原